Register for our free email digests:
Nuron Biotech Inc.
Latest From Ivax Corp.
This week's roundup includes CEO appointments by Eton Pharmaceuticals, the Biotechnology Innovation Organization and Hikma, in addition to various other high-level appointments by Astellas, Akili Interactive Labs and Oxford BioDynamics.
With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.
Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Nuron Biotech Inc.
- Senior Management
Warren D Cooper, Interim Pres. & CEO
Daniel Cushing, PhD, SVP, R&D
Robert J Caso, VP, Fin. & Admin.
- Contact Info
Nuron Biotech Inc.
Phone: (610) 968-6700
1 E. Uwchlan Ave.
Exton, PA 19341
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.